Mercado mundial de terapias para enfermedades monogénicas: tendencias de la industria y pronóstico hasta 2028

Análisis y perspectivas del mercado: mercado mundial de terapias para enfermedades monogénicas

Se espera que el mercado mundial de terapias para enfermedades monogénicas crezca en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza el mercado para tener en cuenta el crecimiento a una tasa compuesta anual del 5 % en el período de pronóstico mencionado anteriormente. El informe de Data Bridge Market Research sobre el mercado de terapias para enfermedades monogénicas proporciona análisis e información sobre los diversos factores que se espera que prevalezcan durante el período de pronóstico, al tiempo que proporciona sus impactos en el crecimiento del mercado.

Las enfermedades monogénicas son el resultado de la mutación o cambio en la secuencia de ADN de un gen. El funcionamiento normal de la proteína presente en su composición se ve obstaculizado por un gen mutado y posteriormente da lugar a los diversos tipos de trastornos monogénicos como la fibrosis quística, la anemia falciforme, la enfermedad de Gaucher, la SCID y otras.

El aumento de la incidencia de enfermedades monogenéticas, el avance en las tecnologías de tratamiento, la creciente conciencia hacia las enfermedades genéticas, el creciente avance en el desarrollo de nuevos fármacos y el aumento de la infraestructura de atención médica son factores impulsores del crecimiento del mercado mundial de terapias para enfermedades monogenéticas.

Se espera que el aumento en el número de actividades de I+D y ensayos clínicos junto con sus tratamientos terapéuticos brinden oportunidades beneficiosas para el mercado global de terapia de enfermedades monogénicas en el período de pronóstico de 2021 a 2028.

Sin embargo, el alto costo asociado con la terapia de enfermedades monogénicas y las menores tasas de éxito de los tratamientos, por ejemplo, la terapia genética, pueden actuar como una restricción y el aumento de los efectos secundarios, junto con las nuevas investigaciones sobre el tratamiento, desafiarán aún más el mercado global de la terapia de enfermedades monogénicas en el período de pronóstico mencionado anteriormente.

This monogenetic disease therapy market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global monogenetic disease therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Monogenetic Disease Therapy Market Scope and Market Size

The monogenetic disease therapy market is segmented on the basis of inheritance pattern, therapy type, application, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of inheritance pattern, the global monogenetic disease therapy market is segmented into autosomal and chromosomal.
• On the basis of therapy type, the global monogenetic disease therapy market is segmented into pharmacological, surgical, blood transfusion, EBRT, gene therapies and others.
• On the basis of application, the global monogenetic disease therapy market is segmented into cystic fibrosis, SCID, sickle cell anemia, phenylketonuria and others.
• On the basis of end-users, the global monogenetic disease therapy market is segmented into clinics, hospitals, diagnostic centres, home healthcare and others.

The global monogenetic disease therapy market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Global Monogenetic Disease Therapy Market Country Level Analysis

Global monogenetic disease therapy market is analyzed and market size information is provided by the country, inheritance pattern, therapy type, application, end-users and distribution channel as referenced above.

The countries covered in the global monogenetic disease therapy market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the monogenetic disease therapy market due to the existence of huge number of players and increasing clinical trials in the region, well-developed healthcare sector and increase in the government support for research & development in this region. Global monogenetic disease therapy market in Europe and the Asia-Pacific is expected to grow during the forecast period, due to the increased occurrence of monogenetic diseases, combined with rising people’s healthcare expenditure.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Global monogenetic disease therapy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to monogenetic disease therapy market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the monogenetic disease therapy market in the growth period.

Competitive Landscape and Global Monogenetic Disease Therapy Market Share Analysis

Global monogenetic disease therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global monogenetic disease therapy market.

The major players covered in the global monogenetic disease therapy market are Abbott Laboratories, BAG Healthcare Gmbh, Novartis AG, Pfizer Inc., Vertex Pharmaceuticals, Bristol-Myers Squibb, F. Hoffmann-La Roche Limited, Bayer AG, Grifols S.A., Bluebird Bio, UniQure and Sanofi S.A. among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

SKU-63526